DVA and CG Related Headlines

Go Back

Mar 17, 2026 07:00AM R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

DVA and CG Related Press Releases

Go Back

Mar 17, 2026 07:00AM R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

DVA and CG Related SEC Filings

Go Back